PLENIBON Trademark

Trademark Overview

On Tuesday, January 17, 2017, a trademark application was filed for PLENIBON with the United States Patent and Trademark Office. The USPTO has given the PLENIBON trademark a serial number of 87303835. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 30, 2020. This trademark is owned by Pfizer Inc.. The PLENIBON trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use
plenibon

General Information

Serial Number87303835
Word MarkPLENIBON
Filing DateTuesday, January 17, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 30, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 29, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 24, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, November 30, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 30, 2020ABANDONMENT - NO USE STATEMENT FILED
Friday, March 20, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 19, 2020EXTENSION 5 GRANTED
Thursday, March 12, 2020EXTENSION 5 FILED
Thursday, March 19, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, March 12, 2020TEAS EXTENSION RECEIVED
Thursday, September 12, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 10, 2019EXTENSION 4 GRANTED
Tuesday, September 10, 2019EXTENSION 4 FILED
Tuesday, September 10, 2019TEAS EXTENSION RECEIVED
Tuesday, March 12, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 8, 2019EXTENSION 3 GRANTED
Friday, March 8, 2019EXTENSION 3 FILED
Friday, March 8, 2019TEAS EXTENSION RECEIVED
Wednesday, October 3, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 1, 2018EXTENSION 2 GRANTED
Monday, October 1, 2018EXTENSION 2 FILED
Monday, October 1, 2018TEAS EXTENSION RECEIVED
Thursday, April 12, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 10, 2018EXTENSION 1 GRANTED
Tuesday, April 10, 2018EXTENSION 1 FILED
Tuesday, April 10, 2018TEAS EXTENSION RECEIVED
Tuesday, October 24, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 29, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 29, 2017PUBLISHED FOR OPPOSITION
Wednesday, August 9, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, July 21, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 19, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 19, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 18, 2017ASSIGNED TO LIE
Monday, June 12, 2017TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, April 10, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, April 10, 2017LETTER OF SUSPENSION E-MAILED
Monday, April 10, 2017SUSPENSION LETTER WRITTEN
Monday, April 10, 2017ASSIGNED TO EXAMINER
Tuesday, January 24, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, January 20, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

plenibon preparations pharmaceutical dysfunction treatment cancer diabetes sexual pain disorders diseases